Two-drug treatment for newly diagnosed myeloma with kidney problems
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, CM336 and isatuximab, for people newly diagnosed with multiple myeloma who also have kidney problems caused by the disease. The goal is to see if this combination can help control the myeloma while also improving kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have newly diagnosed multiple myeloma and have had no more than one cycle of treatment so far.
- Your myeloma is causing kidney problems, specifically a condition called cast nephropathy (a type of kidney damage from myeloma proteins).
- You have measurable signs of myeloma in your blood or urine, or an abnormal free light chain ratio.
- You are generally able to care for yourself (Eastern Cooperative Oncology Group score of 2 or less) and have adequate blood counts, liver function, and blood clotting.
- You do not have active serious infections or severe heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests a new combination of three drugs (F182112, isatuximab, and lenalidomide) for people who have just been diagnosed with multiple myeloma and have had little or no prior treatment. The goal is to see if this combination is safe and effective in controlling the disease.
This study tests a new combination of drugs for people newly diagnosed with a high-risk form of multiple myeloma. The goal is to see if this combination is safe and works better than standard treatments.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.